Combining renin-angiotensin-aldosterone sytem blockade with diuretic therapy for treatment of hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 3, Issue 2, 2002, Pages 72-78

  Motwani, Joseph G ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

ACE inhibition; Angiotensin receptor antagonism; Combination therapy; Hypertension; Thiazide diuretic

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; RAMIPRIL; THIAZIDE DIURETIC AGENT; ANGIOTENSIN RECEPTOR; DIURETIC AGENT;

AGED; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MORBIDITY; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0036614083     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2002.021     Document Type: Review

References (47)

1. Design of potent, competitive inhibitors of angiotensin-converting enzyme carboxyalkanoyl and mercaptoalkanoyl amino acids
2. ACE inhibition in heart failure: Prospects and limitations
3. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
4. Randomised trial of a perindopril-based blood- pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
5. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
6. Principles of combination therapy for hypertension: What we learn from the HOT and other studies - A personal point of view
7. Essential hypertension Part I: Definition and etiology
8. Essential hypertension Part II: Treatment
9. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: Rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors
10. Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure
11. Captopril in essential hypertension: Contrasting effects of adding hydrochlorothiazide or propranolol
12. A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension
13. Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second step treatment of hypertensive patients not controlled by enalapril alone
14. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension
15. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension
16. Captopril evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension
17. Controlled multicentre study of antihypertensive effects of lisinopril, hydrochlorothiazide and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension
18. Short report: Ramipril and hydrochlorothiazide combination therapy in hypertension: A clinical trial of factorial design
19. Anti-hypertensive effectiveness of low-dose hydrochlorothiazide combination. A large multicenter study
20. A diuretic is more effective than a beta blocker in hypertensive patients not controlled on amlodipine and lisinopril
21. Clinical efficacy of perindopril in hypertension
22. Interactive effects of indomethacin, angiotensin II and frusemide on renal haemodynamics and natriuresis in man
23. Randomised trial of old and new antihypertension drugs in elderly patients: Cardiovascular mortality and morbidity of the Swedish Trial in Old Patients with Hypertension-2 study
24. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
25. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
26. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes
27. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy
28. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
29. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
30. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
31. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
32. Angiotensin II receptor antagonists
33. Trial of cardiovascular events in hypertension. Rationale and design
34. British Hypertension Society guidelines for hypertension management 1999: Summary
35. Prevention of events with ACE inhibitor (the PEACE study design)
36. The EUROPA Trial: Design, baseline demography and status of substudies
37. Medical Research Council trial of treatment of hypertension in older adults: Principal results
38. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program
39. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
40. Hypertension and associated metabolic disturbances are related to cognitive impairment. A 20-year follow-up of 999 men
41. Cognitive enhancing actions of DUP 753 detected in a mouse habituation paradigm
42. Study on Cognition and Prognosis in the Elderly (SCOPE)
43. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in Type 2 diabetic patients
44. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients
45. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT)